120 related articles for article (PubMed ID: 16828803)
21. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder.
Guastella AJ; Richardson R; Lovibond PF; Rapee RM; Gaston JE; Mitchell P; Dadds MR
Biol Psychiatry; 2008 Mar; 63(6):544-9. PubMed ID: 18179785
[TBL] [Abstract][Full Text] [Related]
22. A randomized pharmacological fMRI trial investigating D-cycloserine and brain plasticity mechanisms in learned pain responses.
Thomaidou MA; Blythe JS; Veldhuijzen DS; Peerdeman KJ; van Lennep JHPA; Giltay EJ; Cremers HR; Evers AWM
Sci Rep; 2022 Nov; 12(1):19080. PubMed ID: 36351953
[TBL] [Abstract][Full Text] [Related]
23. Randomized controlled experimental study of hydrocortisone and D-cycloserine effects on fear extinction in PTSD.
Inslicht SS; Niles AN; Metzler TJ; Lipshitz SL; Otte C; Milad MR; Orr SP; Marmar CR; Neylan TC
Neuropsychopharmacology; 2022 Oct; 47(11):1945-1952. PubMed ID: 34799682
[TBL] [Abstract][Full Text] [Related]
24. Pharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options.
Garakani A; Murrough JW; Freire RC; Thom RP; Larkin K; Buono FD; Iosifescu DV
Front Psychiatry; 2020; 11():595584. PubMed ID: 33424664
[TBL] [Abstract][Full Text] [Related]
25. BEHAVIORAL AND NEUROBIOLOGICAL MECHANISMS OF PAVLOVIAN AND INSTRUMENTAL EXTINCTION LEARNING.
Bouton ME; Maren S; McNally GP
Physiol Rev; 2021 Apr; 101(2):611-681. PubMed ID: 32970967
[TBL] [Abstract][Full Text] [Related]
26. Randomized controlled trial of d-cycloserine in cocaine dependence: Effects on contingency management and cue-induced cocaine craving in a naturalistic setting.
Johnson MW; Bruner NR; Johnson PS; Silverman K; Berry MS
Exp Clin Psychopharmacol; 2020 Apr; 28(2):157-168. PubMed ID: 31368770
[TBL] [Abstract][Full Text] [Related]
27. A precision medicine approach to pharmacological adjuncts to extinction: a call to broaden research.
King G; Baker KD; Bisby MA; Chan D; Cowan CSM; Stylianakis AA; Zimmermann KS; Richardson R
Psychopharmacology (Berl); 2019 Jan; 236(1):143-161. PubMed ID: 30116858
[TBL] [Abstract][Full Text] [Related]
28. The Efficacy of Augment of D-Cycloserine and Cognitive-behavioral Therapy on Adolescent with one Type of Anxiety Disorders: A Double-blind Randomized Controlled Trial.
Arman S; Soheilimehr A; Maracy MR
Adv Biomed Res; 2017; 6():11. PubMed ID: 28299303
[TBL] [Abstract][Full Text] [Related]
29. Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.
Otto MW; Kredlow MA; Smits JAJ; Hofmann SG; Tolin DF; de Kleine RA; van Minnen A; Evins AE; Pollack MH
Biol Psychiatry; 2016 Aug; 80(4):274-283. PubMed ID: 26520240
[TBL] [Abstract][Full Text] [Related]
30. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale.
Hofmann SG; Carpenter JK; Otto MW; Rosenfield D; Smits JA; Pollack MH
Contemp Clin Trials; 2015 Jul; 43():223-30. PubMed ID: 26111923
[TBL] [Abstract][Full Text] [Related]
31. Augmentation of cognitive and behavioural therapies (CBT) with d-cycloserine for anxiety and related disorders.
Ori R; Amos T; Bergman H; Soares-Weiser K; Ipser JC; Stein DJ
Cochrane Database Syst Rev; 2015 May; 2015(5):CD007803. PubMed ID: 25957940
[TBL] [Abstract][Full Text] [Related]
32. D-cycloserine to enhance extinction of cue-elicited craving for alcohol: a translational approach.
MacKillop J; Few LR; Stojek MK; Murphy CM; Malutinok SF; Johnson FT; Hofmann SG; McGeary JE; Swift RM; Monti PM
Transl Psychiatry; 2015 Apr; 5(4):e544. PubMed ID: 25849983
[TBL] [Abstract][Full Text] [Related]
33. The Future of D-Cycloserine and Other Cognitive Modifiers in Obsessive-Compulsive and Related Disorders.
Sulkowski ML; Geller DA; Lewin AB; Murphy TK; Mittelman A; Brown A; Storch EA
Curr Psychiatry Rev; 2014; 10(4):317-324. PubMed ID: 25383074
[TBL] [Abstract][Full Text] [Related]
34. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders.
Katzman MA; Bleau P; Blier P; Chokka P; Kjernisted K; Van Ameringen M; ; Antony MM; Bouchard S; Brunet A; Flament M; Grigoriadis S; Mendlowitz S; O'Connor K; Rabheru K; Richter PM; Robichaud M; Walker JR
BMC Psychiatry; 2014; 14 Suppl 1(Suppl 1):S1. PubMed ID: 25081580
[TBL] [Abstract][Full Text] [Related]
35. Effects of post-session administration of methylene blue on fear extinction and contextual memory in adults with claustrophobia.
Telch MJ; Bruchey AK; Rosenfield D; Cobb AR; Smits J; Pahl S; Gonzalez-Lima F
Am J Psychiatry; 2014 Oct; 171(10):1091-8. PubMed ID: 25018057
[TBL] [Abstract][Full Text] [Related]
36. Enhancing exposure therapy for anxiety disorders, obsessive-compulsive disorder and post-traumatic stress disorder.
McGuire JF; Lewin AB; Storch EA
Expert Rev Neurother; 2014 Aug; 14(8):893-910. PubMed ID: 24972729
[TBL] [Abstract][Full Text] [Related]
37. Opposing effects of D-cycloserine on fear despite a common extinction duration: interactions between brain regions and behavior.
Bolkan SS; Lattal KM
Neurobiol Learn Mem; 2014 Sep; 113():25-34. PubMed ID: 24374132
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological enhancement of exposure-based treatment in PTSD: a qualitative review.
de Kleine RA; Rothbaum BO; van Minnen A
Eur J Psychotraumatol; 2013 Oct; 4():. PubMed ID: 24147208
[TBL] [Abstract][Full Text] [Related]
39. Cannabinoid modulation of prefrontal-limbic activation during fear extinction learning and recall in humans.
Rabinak CA; Angstadt M; Lyons M; Mori S; Milad MR; Liberzon I; Phan KL
Neurobiol Learn Mem; 2014 Sep; 113():125-34. PubMed ID: 24055595
[TBL] [Abstract][Full Text] [Related]
40. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.
Smits JA; Rosenfield D; Otto MW; Marques L; Davis ML; Meuret AE; Simon NM; Pollack MH; Hofmann SG
J Psychiatr Res; 2013 Oct; 47(10):1455-61. PubMed ID: 23870811
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
